17 Oct Pegah Named to Business Insider’s Top Pioneers In Biotech Venture Capital
This week, Business Insider published its list of the rising stars in biotech investing. To compile this list, Insider reached out to well-known investors, such as Andreessen Horowitz’s Vijay Pande and EcoR1’s Oleg Nodelman; academics such as Yale’s Aaron Ring and MIT’s Andrew Lo; and biotech entrepreneurs including Strand CEO Jake Becraft and Ochre CEO Jack O’Meara.
Pegah Ebrahimi was named to the list of 16 pioneering biotech investors who are taking new approaches to biotech investing and reshaping the industry’s future.
Title and firm: Cofounder and managing partner at FPV Ventures
Years in VC: 4
Notable investments: Ultima Genomics, Strand Therapeutics, Manifold Bio, Enveda Biosciences, Xilis
Ebrahimi cofounded FPV Ventures earlier this year, bringing a new approach to biotech investing along with her cofounder, Wesley Chan. FPV stands for three key focuses for the two VCs, Chan said, with mock names for the company: Founders’ Point of View, First Principles Ventures, and First Phone Call Ventures.
Our understanding of how tech can enable new innovations in life sciences helps us find that next platform that gives an edge/advantage to find the next blockbuster cancer or mRNA therapeutic.
Specifically, they say their unique backgrounds give them a different approach. Chan was a software engineer and founded Google Analytics and Google Voice while working at the tech giant. She also brings 12 years of VC experience. Ebrahimi spent more than 15 years at Morgan Stanley in a variety of roles, working on mergers and acquisitions, VC, and investment banking, including as chief operating officer of global technology banking. Ebrahimi and Chan say their tech and finance backgrounds help their portfolio companies focus on scaling their tech and hiring the right engineers.
“Our understanding of how tech can enable new innovations in life sciences helps us find that next platform that gives an edge/advantage to find the next blockbuster cancer or mRNA therapeutic,” Ebrahimi and Chan wrote in an email.
The two have raised $450 million for FPV’s first fund and are looking to invest in mission-driven founders with big ideas, such as those behind Strand Therapeutics, which is working to bring messenger RNA beyond vaccines to therapeutics.
Hover Box Element
FPV Ventures Founders
Felicis’ Chan made early bets on Robinhood, Gusto and Plaid. Ebrahimi was COO of Morgan Stanley global technology banking
FPV Founders, Pegah Ebrahimi & Wesley Chan.